Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to prop open the sinus ostia following endoscopic sinus surgery. As the implant dissolves, medicine is delivered directly to the sinus lining. Get the full story at our […]
Otolaryngology/Ear, Nose & Throat (ENT)
Intersect ENT tops estimates with Q3 results
Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$7.6 million on sales of $24.7 million for the 3 months ended Sept. 30, for sales growth of 11% compared with the same period last […]
Earlens closes $87m offering
Earlens said today it closed an $87 million round of financing to help support continued development and a next-gen rollout of its hearing aid technology. The round was led by newly invested KCK Ltd., and joined by Exor Seets and previously invested Lightstone Ventures, CRG Partners, Windham Life Sciences Partners, Arch Healthcare, Relativity Health Fund, […]
FDA grants de novo nod for Bose self-fitted hearing aid
The FDA today said it granted de novo clearance to a self-fitted hearing aid made by Bose Corp. for adults with mild to moderate hearing loss. The Bose Hearing Aid is designed to allow the patient to fit, program and control the hearing aid without help from a healthcare provider, the first such device on the […]
Inside Spirox: The challenges and successes of a physician-entrepreneur
This is the first podcast in a series produced with MPR, a product development firm that thrives on creating breakthrough products. Thanks for listening and we hope you enjoy this interview with physician-entrepreneur Dr. Iyad Saidi. The story of Spirox and its bioresorbable nasal implant is one of great success – the company sold to […]
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in the […]
Anthem adds Intersect ENT’s Sinuva implant to formulary
Anthem this month added Intersect ENT‘s (NSDQ:XENT) Sinuva steroid-releasing implant to its updated formulary as a Tier 3 product, according to a note from Leerink analysts. The product is designated on Anthem’s formulary as “LD” – limited distribution – and is only available to certain pharmacies or wholesalers. Intersect ENT launched the product in the U.S. in April this year. Get the […]
Advanced Bionics wins FDA nod for MRI-safe HiRes Ultra 3D cochlear implant
Sonova Holding AG (SIX:SOON) subsidiary Advanced Bionics said yesterday that it won FDA approval for its HiRes Ultra 3D cochlear implant. The newly approved implant is cleared for use during magnetic resonance imaging examinations as it features a new magnet design which provides alignment with an external magnetic field in any direction. The magnet allows users […]
GN Hearing inks deal with Google, launches Beltone Amaze
GN Hearing (CPH:GN) this week announced it inked a partnership with Google (NSDQ:GOOG) to enable its hearing aid devices to directly stream audio from Android devices, and said it launched its Beltone Amaze hearing solution. With the Google deal, users will be able to connect and monitor their hearing aids on Android devices as well as […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up visit […]
Intersect ENT shares tumble on Q2 results
Shares in Intersect ENT (NSDQ:XENT) fell today after the medical device maker missed sales expectations on Wall Street with its second-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$4.2 million on sales of $26.3 million for the 3 months ended June 30, for sales growth of 9.7% compared with the same period […]